D-Index & Metrics Best Publications

Ann K. Daly

Newcastle University
United Kingdom

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name Citations Publications World Ranking National Ranking

Medicine D-index 99 Citations 35,144 396 World Ranking 5149 National Ranking 504

Best female scientists D-index 99 Citations 35,152 402 World Ranking 975 National Ranking 95

Research.com Recognitions

Awards & Achievements

2023 - Research.com Best Female Scientist Award

2022 - Research.com Best Female Scientist Award

Overview

What are the main themes of her work throughout her whole career to date

Her Gastroenterology research is intertwined with Alanine aminotransferase and Steatosis. Her Alanine aminotransferase study often links to related topics such as Gastroenterology. Steatosis and Fatty liver are two areas of study in which Ann K. Daly engages in interdisciplinary work. Her study ties her expertise on Disease together with the subject of Fatty liver. Ann K. Daly performs multidisciplinary studies into Disease and Gene in her work. Gene is a subfield of Genetic model that Ann K. Daly investigates. Her Genetics research extends to Genetic model, which is thematically connected. Her research links Arylamine N-acetyltransferase with Genetics. Her work on Genotype expands to the thematically related Arylamine N-acetyltransferase.

Ann K. Daly most often published in these fields:

Genetics (100.00%)
Gene (66.67%)
CYP2A6 (50.00%)

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression.

Peter Kuehl;Jiong Zhang;Yvonne Lin;Jatinder Lamba.
Nature Genetics (2001)

2547 Citations

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

Guruprasad P Aithal;Christopher P Day;Patrick J L Kesteven;Ann K Daly.
The Lancet (1999)

1638 Citations

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: Proposal for a new dosing regimen

Elizabeth A. Sconce;Tayyaba I. Khan;Tayyaba I. Khan;Hilary A. Wynne;Hilary A. Wynne;Peter Avery;Peter Avery.
Blood (2005)

1208 Citations

Metabolic gene polymorphism frequencies in control populations.

S. Garte;L. Gaspari;A.K. Alexandrie;C. Ambrosone.
Cancer Epidemiology, Biomarkers & Prevention (2001)

1103 Citations

HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin.

Ann K Daly;Peter T Donaldson;Pallav Bhatnagar;Yufeng Shen.
Nature Genetics (2009)

1068 Citations

Case definition and phenotype standardization in drug-induced liver injury

GP Aithal;PB Watkins;RJ Andrade;D Larrey.
Clinical Pharmacology & Therapeutics (2011)

903 Citations

A Randomized Trial of Genotype-Guided Dosing of Warfarin

Munir Pirmohamed;Girvan Burnside;Niclas Eriksson;Andrea L. Jorgensen.
The New England Journal of Medicine (2013)

870 Citations

Homozygosity for the patatin-like phospholipase-3/adiponutrin i148m polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease

Luca Valenti;Ahmad Al-Serri;Ann K. Daly;Enrico Galmozzi.
Hepatology (2010)

616 Citations

Nomenclature for human CYP2D6 alleles.

A K Daly;J Brockmoller;F Broly;M Eichelbaum.
Pharmacogenetics (1996)

583 Citations

TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease

Yang-Lin Liu;Helen L Reeves;Alastair D Burt;Dina Tiniakos.
Nature Communications (2014)

531 Citations

If you think any of the details on this page are incorrect, let us know.